Sotorasib after immune checkpoint inhibitor administration induces hepatotoxicity. True, false or just another adverse effect of NSCLC treatment

Tsoulos, 2017, Tumor molecular profiling of NSCLC patients using next generation sequencing, Oncol. Rep., 38, 3419 Gendarme, 2022, ROS-1 fusions in non-small-cell lung cancer: evidence to date, Curr. Oncol., 29, 641, 10.3390/curroncol29020057 Di Noia, 2021, Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies, ESMO Open, 6, 10.1016/j.esmoop.2021.100280 Zhu, 2021, MET inhibitor, capmatinib overcomes osimertinib resistance via suppression of MET/Akt/snail signaling in non-small cell lung cancer and decreased generation of cancer-associated fibroblasts, Aging, 13, 6890, 10.18632/aging.202547 Cheng, 2021, Therapeutic advances in non-small cell lung cancer: focus on clinical development of targeted therapy and immunotherapy, MedComm, 2, 692, 10.1002/mco2.105 Mielgo-Rubio, 2021, Immunotherapy in non-small cell lung cancer: update and new insights, J. Clin. Transl. Res., 7, 1 Righi, 2017, Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)-from morphology to molecular testing, J. Thorac. Dis., 9, S395, 10.21037/jtd.2017.03.158 Rolfo, 2021, Liquid biopsy for advanced NSCLC: a consensus statement from the international association for the study of lung cancer, J. Thorac. Oncol., 16, 1647, 10.1016/j.jtho.2021.06.017 Zarogoulidis, 2023, Endobronchial Radiofrequency Ablation for pulmonary nodules with Radial–Ebus and navigation: pros and cons, J. Cancer, 14, 1562, 10.7150/jca.84894 Zarogoulidis, 2022, Radial-EBUS: CryoBiopsy versus conventional biopsy: time-sample and C-arm, Int. J. Environ. Res. Public Health, 19, 10.3390/ijerph19063569 Zarogoulidis, 2020, Lung cancer biopsies: comparison between simple 22G, 22G upgraded and 21G needle for EBUS-TBNA, J. Cancer, 11, 6454, 10.7150/jca.48691 2014, Comprehensive molecular profiling of lung adenocarcinoma, Nature, 511, 543, 10.1038/nature13385 Dearden, 2013, Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap), Ann. Oncol., 24, 2371, 10.1093/annonc/mdt205 Roman, 2018, KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target, Mol. Cancer, 17, 33, 10.1186/s12943-018-0789-x Kris, 2014, Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs, JAMA, 311, 1998, 10.1001/jama.2014.3741 Janne, 2017, Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS-mutant advanced non-small cell lung cancer: the SELECT-1 randomized clinical trial, JAMA, 317, 1844, 10.1001/jama.2017.3438 Gandara, 2017, A phase 1/1b study evaluating trametinib plus docetaxel or pemetrexed in patients with advanced non-small cell lung cancer, J. Thorac. Oncol., 12, 556, 10.1016/j.jtho.2016.11.2218 Desai, 2023, Time from immune checkpoint inhibitor to sotorasib use correlates with risk of hepatotoxicity in non-small cell lung cancer: a brief report, Cancer Treat. Res. Commun., 36 Ahn, 2022, Osimertinib plus durvalumab in patients with EGFR-mutated, advanced NSCLC: a phase 1b, open-label, multicenter trial, J. Thorac. Oncol., 17, 718, 10.1016/j.jtho.2022.01.012 Lin, 2019, Increased hepatotoxicity associated with sequential immune checkpoint inhibitor and crizotinib therapy in patients with non-small cell lung cancer, J. Thorac. Oncol., 14, 135, 10.1016/j.jtho.2018.09.001 Canon, 2019, The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumor immunity, Nature, 575, 217, 10.1038/s41586-019-1694-1